Invesco’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-63,537
| Closed | -$193K | – | 3841 |
|
|
2024
Q4 | $193K | Buy |
63,537
+7,125
| +13% | +$31K | ﹤0.01% | 3524 |
|
|
2024
Q3 | $293K | Sell |
56,412
-6,271
| -10% | -$31.2K | ﹤0.01% | 3427 |
|
|
2024
Q2 | $161K | Buy |
62,683
+11,749
| +23% | +$40.1K | ﹤0.01% | 3679 |
|
|
2024
Q1 | $251K | Sell |
50,934
-1,551,688
| -97% | -$9.18M | ﹤0.01% | 3576 |
|
|
2023
Q4 | $14.1M | Sell |
1,602,622
-1,299,818
| -45% | -$10.6M | ﹤0.01% | 1603 |
|
|
2023
Q3 | $33.3M | Buy |
2,902,440
+1,153,615
| +66% | +$22.2M | 0.01% | 1121 |
|
|
2023
Q2 | $44.3M | Buy |
1,748,825
+1,527,259
| +689% | +$47.6M | 0.01% | 991 |
|
|
2023
Q1 | $7.14M | Buy |
221,566
+155,131
| +234% | +$4.84M | ﹤0.01% | 2040 |
|
|
2022
Q4 | $1.23M | Sell |
66,435
-174,255
| -72% | -$3.99M | ﹤0.01% | 2840 |
|
|
2022
Q3 | $6.5M | Buy |
240,690
+177,802
| +283% | +$3.61M | ﹤0.01% | 2059 |
|
|
2022
Q2 | $869K | Sell |
62,888
-155,458
| -71% | -$2.39M | ﹤0.01% | 3041 |
|
|
2022
Q1 | $4.26M | Buy |
218,346
+178,955
| +454% | +$2.71M | ﹤0.01% | 2449 |
|
|
2021
Q4 | $643K | Sell |
39,391
-2,683
| -6% | -$44.7K | ﹤0.01% | 3281 |
|
|
2021
Q3 | $1.17M | Buy |
42,074
+5,377
| +15% | +$153K | ﹤0.01% | 3036 |
|
|
2021
Q2 | $1.09M | Buy |
36,697
+10,012
| +38% | +$289K | ﹤0.01% | 3099 |
|
|
2021
Q1 | $746K | Buy |
26,685
+12,665
| +90% | +$350K | ﹤0.01% | 3174 |
|
|
2020
Q4 | $398K | Sell |
14,020
-21,945
| -61% | -$568K | ﹤0.01% | 3299 |
|
|
2020
Q3 | $904K | Buy |
35,965
+4,288
| +14% | +$112K | ﹤0.01% | 2867 |
|
|
2020
Q2 | $773K | Buy |
+31,677
| New | +$625K | ﹤0.01% | 2926 |
|
|
2020
Q1 | – | Sell |
-11,866
| Closed | -$193K | – | 3742 |
|
|
2019
Q4 | $193K | Sell |
11,866
-768
| -6% | -$11.9K | ﹤0.01% | 3535 |
|
|
2019
Q3 | $164K | Sell |
12,634
-492
| -4% | -$6.02K | ﹤0.01% | 3579 |
|
|
2019
Q2 | $170K | Sell |
13,126
-5,981
| -31% | -$75.4K | ﹤0.01% | 3636 |
|
|
2019
Q1 | $301K | Buy |
+19,107
| New | +$331K | ﹤0.01% | 3486 |
|
|
2018
Q2 | – | Sell |
-83,097
| Closed | -$2.56M | – | 3926 |
|
|
2018
Q1 | $2.56M | Buy |
+83,097
| New | +$2.67M | ﹤0.01% | 2396 |
|
|
2016
Q2 | – | Sell |
-69,594
| Closed | -$1.22M | – | 3728 |
|
|
2016
Q1 | $1.22M | Buy |
+69,594
| New | +$1.42M | ﹤0.01% | 2798 |
|
|
2015
Q3 | – | Sell |
-161
| Closed | -$5K | – | 4021 |
|
|
2015
Q2 | $5K | Buy |
+161
| New | +$4.14K | ﹤0.01% | 4223 |
|
Other funds holding RVNC
Invesco's RVNC Position: Q1 2025 in Review
Invesco sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 63,537 shares — an estimated $193K sold.
Invesco first reported a position in RVNC in Q2 2015 and held it in 26 quarters. The position peaked at $44.3M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Invesco reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Invesco sold 63,537 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $193K.
- Invesco first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 26 quarters.
- Invesco's Revance Therapeutics, Inc. position peaked at $44.3M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Invesco's 13F filing for Q1 2025, filed 12 May 2025.